Table 2.
Characteristics of adult malignant and nonmalignant hematology studies.
| Source (country) | Condition | Sample size and age | Study design | Study setting | Grade |
| Agrawal 2014 [51] (India) | Blood transfusion donors | N=16,438 donations | Pilot study | Regional Blood Transfusion Centre (Dehradun, Uttarakhand) | Very low |
| Applebaum 2012 [52] (United States) | Posttraumatic stress disorder related to hematopoietic stem cell transplantation | N=46 | Randomized controlled trial | Memorial Sloan-Kettering Cancer Center, Mount Sinai Medical Center, and Hackensack University Medical Center | Moderate |
| Bakitas 2015 [53] (United States) | Advanced-stage solid tumor or hematological malignancy with oncologist-determined prognosis of 6-24 months | N=207; early group mean age: 64.03 years, delayed group mean age: 64.6 years | Randomized controlled trial | National Cancer Institute Center and Veterans Affairs Medical Center | Moderate |
| Barcellona 2013 [54] (Italy) | Thromboembolic conditions | N=114; mean age: 61 years | Pre-post study | Thrombosis centers | Low |
| Blissit 2015 [55] (United States) | Thromboembolic conditions | N=200; face-to-face group (n=90) and telephone group (n=110) | Retrospective study | Veterans Affairs Medical Center and affiliated rural clinics in South Carolina | Very low |
| Breen 2015 [42] (Australia) | Hodgkin/non-Hodgkin lymphoma and chronic lymphocytic leukemia | N=18; mean age: 48.4 years | Pilot study | Chemotherapy day unit and hematology inpatient ward | Very low |
| Burwick 2018 [56] (United States) | Monoclonal gammopathy of undetermined significance | N=152; median age: 69 years | Retrospective study | Veterans Health Administration facilities | Very low |
| Cecchini 2016 [57] (United States) | Varying hematological conditions (majority anemia, thrombocytopenia, and venous thromboembolism) | N=909; e-consult (n=302), median age: 64 years; face-to-face consult before e-consult (n=305), median age: 69.3 years; face-to-face consult after e-consult (n=302), median age: 65.9 years | Retrospective study | Veterans Affairs Connecticut Healthcare System | Very low |
| Clarke 2011 [58] (Canada) | Cancer (majority gastrointestinal and lymphoma) | N=712 | Retrospective study | 48 Local Health Areas (British Columbia, Canada) | Very low |
| Compaci 2011 [59] (France) | Diffuse large B-cell lymphoma | N=100; median age: 57 years | Noncomparative prospective study | Toulouse University Hospital | Very low |
| Flannery 2009 [60] (United States) | Medical oncology and hematologic malignant diagnoses | N=5283; mean age 61.1 years | Descriptive retrospective study | University of Rochester Medical Center and James P. Wilmot Cancer Center | Very low |
| Hung 2014 [61] (Australia) | Hematological malignancies in patients who received peripheral blood stem cell transplants | N=37; usual care (n=19), age: 59.9 years; extended care (n=18), age: 57.5 years | Randomized controlled trial | The Hematology and Oncology Clinics of Australia, The Wesley Hospital (Brisbane, Australia) | Low |
| Kirsh 2015 [62] (United States) | Hematology and other specialties | N=217,014 | Pilot study | Veterans Health Administration and Veterans Integrated Service Networks | Very low |
| Najafi 2017 [63] (United States) | Hematology and other specialties | N=313 (63 hematology) | Pilot study | University of California San Francisco Hospital in Mission Bay | Very low |
| Overend 2008 [64] (Canada) | Indolent and chronic hematological malignancies | N=53; median age: 66.5 years | Pilot study | British Columbia Cancer Agency’s Centre for the Southern Interior in Kelowna | Very low |
| Philip 2015 [65] (United States) | Thromboembolic conditions | N=502 | Pilot study | Harris Health System (Houston, Texas) | Very low |
| Prochaska 2017 [66] (Germany) | Thromboembolic conditions in patients receiving vitamin K antagonists | N=2221; median age: 73 years | Prospective cohort study | Center of Thrombosis and Hemostasis, University Medical Center Mainz | Very low |
| Reid 2011 [67] (Ireland) | Cancer | N=7498 | Retrospective study | Regional Cancer Centre | Very low |
| Skeith 2017 [68] (Canada) | Thromboembolic conditions | N=162; mean age: 58.3 years | Cross-sectional study | Champlain Local Health Integration Network (Ontario, Canada) | Very low |
| Syrjala 2011 [69] (United States) | Cancer survivors treated with hemopoietic stem cell transplantation | N=775; mean age: 51.7 years | Randomized controlled trial | Fred Hutchinson Cancer Research Center (Seattle, Washington) | Moderate |
| Testa 2005 [70] (Italy) | Thromboembolic conditions | N=1393 | Retrospective study | 11 peripheral health care units and homes of 20 self-testing patients | Low |
| Woods 2000 [72] (United States) | Sickle cell disease | N=466; mean age: 27 years | Retrospective study | Telemedicine clinical sites of The Medical College of Georgia Sickle Cell Center (Augusta, Georgia) | Very low |
| Woods 1999 [73] (United States) | Sickle cell disease | N=120; standard (n=60), age: 33.32 years; telemedicine (n=60), age: 29.37 years | Randomized controlled trial | Telemedicine clinical sites of The Medical College of Georgia Sickle Cell Center (Augusta, Georgia) | Very low |
| Woods 1998 [71] (United States) | Sickle cell disease | N=28; mean age: 29.1 years | Pilot study | Remote telemedicine clinic site in Macon (affiliated with Medical Center of Central Georgia) | Very low |
| Wright 2007 [74] (Canada) | Allogenic blood and hemopoietic stem cell transplantation | N=1 | Case study | Princess Margaret Hospital (Toronto, Ontario) | Very low |